Merck & Company (MRK) |
80.25 -0.9 (-1.11%)
|
01-27 06:08 |
Open: |
81.15 |
Pre. Close: |
81.15 |
High:
|
81.15 |
Low:
|
80.13 |
Volume:
|
7,139,482 |
Market Cap:
|
203,035M |
|
|
Merck & Co., Inc. provides healthcare solutions worldwide. The company offers therapeutic and preventive agents for cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases; neuromuscular blocking agents; cholesterol modifying medicines; and anti-bacterial and vaginal contraceptive products. It provides products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat non-small-cell lung, ovarian and breast, esophageal, thyroid, cervical, and brain cancers; and prevent diseases caused by human papillomavirus, as well as vaccines for measles, mumps, rubella, varicella, shingles, rotavirus gastroenteritis, and pneumococcal diseases. In addition, the company offers drugs for hepatocellular and merkel cell carcinoma; antibiotic and anti-inflammatory drugs for infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, bovine, and swine; vaccines for poultry; parasiticides for sea lice in salmon; and antibiotics and vaccines for fish. Further, it provides companion animal products; diabetes mellitus treatment and anthelmintic products for dogs and cats; products to treat fleas, ticks, mosquitoes, and sandflies; horse fertility management products for swine; and dog, cat, and horse vaccines. Additionally, the company offers services and solutions that focus on engagement, clinical, and health analytics. Merck & Co., Inc. has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Almac Discovery Ltd.; Skyhawk Therapeutics, Inc.; Ridgeback Biotherapeutics; Shanghai Junshi Biosciences Co., Ltd.; FUJIFILM Corporation; Intec Pharma Ltd.; and Transcenta Holding Ltd. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers; and physicians and physician distributors, veterinarians, and animal producers. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey. |
Stock Price Prediction |
Update at 5:00pm EST |
If tomorrow:
|
Open lower
|
Open higher
|
High:
|
81.38 - 81.831 |
81.831 - 82.197 |
Low:
|
78.717 - 79.364 |
79.364 - 79.89 |
Close:
|
79.303 - 80.258 |
80.258 - 81.034 |
|
Technical analysis |
as of: 2021-01-26 4:46:38 PM |
Overall:
|
|
Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
Target: |
Six months: 96.47 One year: 99.98 |
Support: |
Support1: 77.74 Support2: 64.68 |
Resistance: |
Resistance1: 82.60 Resistance2: 85.60 |
Pivot: |
82.38  |
Moving Average: |
MA(5): 81.20 MA(20): 82.05 
MA(100): 81.28 MA(250): 80.31  |
MACD: |
MACD(12,26): 0.04 Signal(9): 0.35  |
Stochastic oscillator: |
%K(14,3): 15.80 %D(3): 22.07  |
RSI: |
RSI(14): 42.75  |
52-week: |
High: 89.20 Low: 65.25 Change(%): -8.0 |
Average Vol(K): |
3-Month: 897016 10-Days: 928126 |
|
Price, moving averages and Bollinger Bands |
Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.MRK has closed above bottom band by 7.2%. Bollinger Bands are 2.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
Headline News |
Tue, 26 Jan 2021 Merck scraps Covid-19 vaccine programs after they fail to measure up on efficacy in another major setback in the global fight - Endpoints News
Tue, 26 Jan 2021 Merck Announces Second-Quarter 2021 Dividend - Business Wire
Tue, 26 Jan 2021 Merck Halts Development Of Coronavirus Vaccines - The Onion
Mon, 25 Jan 2021 Judge orders Merck documents on anti-baldness drug Propecia unsealed - Reuters
Mon, 25 Jan 2021 Berkshire Holding Merck Dips on Covid-19 Vaccine Program Termination - Yahoo Finance
Mon, 25 Jan 2021 Vaccine Roundup: Merck Wipes Out (and More) | In the Pipeline - Science Magazine
|
Financial Analysis |
Growth |
 |
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
Profitability |
 |
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
Solvency |
 |
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
Efficiency |
 |
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
Return on Assets: |
Neutral |
Price to Earnings: |
Outperform |
Return on Equity: |
Outperform |
Debt to Equity: |
Outperform |
|
|
|
|
|
Free Technical Analysis Charts
|
|
Stock Basics & Statistics |
Exchange: NYSE |
Sector: Healthcare |
Industry: Drug Manufacturers General |
Shares Out. (M) |
2,530 |
Shares Float (M) |
2,510 |
% Held by Insiders
|
0.08 |
% Held by Institutions
|
75.98 |
Shares Short (K)
|
13,590 |
Shares Short P. Month (K)
|
13,460 |
Stock Financials |
EPS
|
4.530 |
EPS Est This Year
|
3.870 |
EPS Est Next Year
|
4.160 |
Book Value (p.s.)
|
11.540 |
Profit Margin
|
24.33 |
Operating Margin
|
32.95 |
Return on Assets (ttm)
|
11.3 |
Return on Equity (ttm)
|
41.1 |
Qtrly Rev. Growth
|
1.2 |
Gross Profit (p.s.)
|
13.312 |
Sales Per Share
|
18.715 |
EBITDA (p.s.)
|
7.514 |
Qtrly Earnings Growth
|
54.70 |
Operating Cash Flow (M)
|
11,040 |
Levered Free Cash Flow (M)
|
8,650 |
Stock Valuations |
PE Ratio
|
17.72 |
PEG Ratio
|
1.26 |
Price to Book value
|
6.95 |
Price to Sales
|
4.29 |
Price to Cash Flow
|
18.39 |
Stock Dividends |
Dividend
|
2.380 |
Forward Dividend
|
2.600 |
Dividend Yield
|
0.03 |
Dividend Pay Date
|
2021-01-07 |
Ex-Dividend Date
|
2020-12-13 |
7 Binary Options
|
Your Ad Here
|
|